Research graph
References from Patient Survival and Its Relation to Tumor Absorbed Dose in [ 177 Lu]Lu-DOTATATE Therapy of Neuroendocrine Tumors. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/s1470-2045(21)00572-6
10.1016/s1470-2045(21)00572-6 · External reference
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
10.1007/s00259-018-4209-7 · 2019 · External reference
10.1007/s00259-018-3945-z
10.1007/s00259-018-3945-z · External reference
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
10.1007/s00259-022-05786-w · 2022 · External reference
10.2967/jnumed.114.148437
10.2967/jnumed.114.148437 · External reference
Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE; differences in tumor dosimetry, vascularity and lesion metrics in pancreatic and small intestinal neuroendocrine neoplasms
10.3390/cancers13050962 · 2021 · External reference
10.2967/jnumed.123.266991
10.2967/jnumed.123.266991 · External reference
The relationship between tumour dosimetry, response, and overall survival in patients with unresectable neuroendocrine neoplasms (NEN) treated with 177Lu DOTATATE (LuTate)
10.1007/s00259-023-06257-6 · 2023 · External reference
Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
10.1186/s40658-024-00620-8 · 2024 · External reference
10.2967/jnumed.123.267023
10.2967/jnumed.123.267023 · External reference
The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE
10.1007/s00259-024-06863-y · 2024 · External reference
10.2967/jnumed.123.265987
10.2967/jnumed.123.265987 · External reference
10.1016/j.ejca.2016.03.081
10.1016/j.ejca.2016.03.081 · External reference
A 3-dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy: evaluation for 131I using Monte Carlo simulation
2002 · External reference
10.1089/108497803321269377
10.1089/108497803321269377 · External reference
10.1109/nssmic.1996.591559
10.1109/nssmic.1996.591559 · External reference
10.1098/rspb.1980.0020
10.1098/rspb.1980.0020 · External reference
10.2967/jnumed.121.262069
10.2967/jnumed.121.262069 · External reference
10.1007/s00259-022-05727-7
10.1007/s00259-022-05727-7 · External reference
Averaging of absorbed doses: how matter matters
10.1002/mp.16528 · 2023 · External reference
10.1177/003591576505800503
10.1177/003591576505800503 · External reference
Dose–response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases
10.1007/s00259-021-05642-3 · 2022 · External reference
10.2967/jnumed.124.269389
10.2967/jnumed.124.269389 · External reference
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study
10.1186/s13550-024-01163-w · 2024 · External reference
10.2967/jnumed.124.268880
10.2967/jnumed.124.268880 · External reference
